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A B S T R A C T
Despite the undeniable progress in the development of new effective drugs against 
malignant and non-malignant hematological diseases, allogeneic hematopoietic stem 
cell transplantation (HSCT) remains the only therapeutic option with long lasting 
curative potential. Continuous research for the last fifty years has repeatedly shown 
that human leukocyte antigen (HLA) compatibility between recipient and donor con-
stitutes the most decisive factor for successful engraftment and higher rates of over-
all survival. Unfortunately, a fully HLA matched donor is in many cases precluded, 
therefore the identification of better tolerated HLA mismatches has always been and 
still remains an important research objective. In this review we recapitulate current 
knowledge on how HLA- (i.e. locus, resolution level, directionality, number etc.) as 
well as non-HLA factors (i.e. disease stage, recipient age, graft source etc.) may im-
pact the overall effect of HLA incompatibility on HSCT outcome, with the aim to 
offer an overview on potentially “permissive” HLA mismatches.
I N T R O D U C T I O N 
The first hematopoietic stem cell transplantation (HSCT) clinical trials date back 
in the middle 50’s, as E. D. Thomas in the United States and G. Mathé in Europe 
were the first to perform allogeneic HSCT in humans.1,2 These initial efforts had 
minimal success as they were compromised by the lack of knowledge on the pivotal 
role of histocompatibility in transplantation. The discovery of the human leukocyte 
antigen (HLA) System3 in conjunction with the development of the first HLA typing 
methods allowed better understanding of the immunobiological processes implicated 
in post HSCT engraftment, graft versus host disease (GvHD) and leukemia relapse. 
Since then hundreds of thousands of HSCTs have been performed with the millionth 
being reported by the Worldwide Network for Blood and Marrow Transplantation 
in December 2012.4 Tremendous progress in HLA typing,5 conditioning regimens as 
well as infection control and GvHD prophylaxis treatments have rendered this initially 
experimental therapeutic approach into a standard-of-care treatment for a plethora 
of benign as well as malignant disorders.6 The steadily growing number of volunteer 
donors registered in the Bone Marrow Donor Worldwide (BMDW) database, which 
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appears to have surpassed the threshold of 35,900,000 in Au-
gust 2019 (www.bmdw.org), has also contributed immensely 
to this development. 
Despite this irrefutable progress, HSCT remains a high-
risk treatment associated with high mortality rates due to 
transplantation-related morbidity factors such as GvHD, 
toxicity and severe infection, with patient/donor HLA-com-
patibility being long established as the most decisive donor-
parameter influencing HSCT outcome.7 An HLA-identical 
sibling donor is still considered the gold standard. However, it 
is readily available for only about 30% of patients. From those 
remaining,  only half (i.e. 35% overall) will be able to find a 
10/10 HLA matched unrelated donor (MUD)(i.e. matched 
for HLA-A,-B,-C,-DRB1 and –DQB1), a percentage that will 
probably decrease in the future, as the broad implementa-
tion of whole gene HLA typing will likely stress the need to 
consider additional HLA regions upon donor selection, apart 
from those determining the antigen recognition site (ARS)
(i.e. exon 2 and 3 for HLA-class I and exon 2 for HLA-class 
II, respectively).8  In fact it has been recently reported that 
HLA-matching at max-resolution level (i.e. inclusion of non-
ARS regions for allele assignment) may lower GvHD rates 
and overall improve HSCT outcome9,10 although more stud-
ies are required before definitive conclusions are drawn. It 
should be noted, however, that despite the aforementioned 
findings, mismatches outside the ARS are not considered as 
mismatches in daily practice with the exception of course of 
null alleles. Furthermore, many studies have clearly shown 
that even mismatches in loci that are viewed as secondary in 
significance, like DQB1, DPB1 and DRB3/4/5 may adversely 
affect HSCT outcome in a cumulative fashion.11-13 The fact 
that for more than half of the patients at least one major 
(i.e. HLA-A,-B,-C and -DRB1) or minor (i.e. HLA-DQB1,-
DPB1 and -DRB3/4/5) HLA mismatch will be inevitable, 
explains the large number of studies aiming at identifying 
so-called ‘permissive’ HLA mismatches.14 Moreover, the 
fact that non-HLA parameters such as recipient age, disease 
stage, conditioning regimen, cytomegalovirus (CMV)-sero-
compatibility etc. have been clearly shown to differentially 
influence HLA-mismatch impact on HSCT outcome,12,15-19 
renders consensus as to ‘mismatch-permissiveness’ extremely 
difficult and underscores the necessity for larger and more 
homogenous cohorts. 
Aim of this review is to recapitulate current knowledge on 
how HLA- (i.e. locus, resolution level, directionality, number 
etc.) as well as non-HLA factors (i.e. disease stage, recipient 
age, graft source etc.) may impact the overall effect of HLA 
incompatibility on HSCT outcome. Certain recommendations 
on how assessment of multiple parameters can potentially 
lead to optimal, patient-tailored donor selection are outlined 
in the conclusions part.
H L A  f A C T O R S  T H A T  I N f L U e N C e  
T H e  I m p A C T  O f  H L A  D I S p A R I T y  
O N  H S C T  O U T C O m e 
In this section we sought to shed some light on all the HLA-
relevant factors that appear to affect the overall impact of 
distinct HLA incompatibilities on HSCT outcome. Apart from 
locus and number of HLA discrepancies, mismatch resolution 
level along with mismatch directionality are being addressed. 
Finally, the HLA discrepancies located in HLA-C and HLA-
DPB1 are discussed separately, as incompatibilities in these 
two loci appear to share features that clearly distinguish them 
from the other HLA loci. 
L O C U S
Although there is general consensus on the fact that HLA-
disparities lead to poorer post-transplant outcome, there is 
still a lot of controversy over the differential contribution of 
each HLA-locus mismatch to this negative effect. According 
to current standards20 applied worldwide, a donor that is fully 
compatible with the patient at second-field/allele (high-reso-
lution) typing level for the loci A, B, C, DRB1 +/-DQB1 (i.e. 
8/8 or 10/10 matched in the US and in Europe, respectively) 
is defined as fully HLA matched. In Table 1 are listed some 
of the most representative studies,13,16,17,21-28 that have tried to 
estimate the impact of respective HLA-locus disparities on 
mortality. Regardless of their heterogeneity as to some basic 
transplantation-related parameters like graft source, trans-
plantation time period, patient age and conditioning regimen, 
most of them have reported significantly higher mortality 
risk ratios for mismatches concerning HLA-class I antigens. 
There appears to be also consensus on the minimal impact of 
single HLA-DQB1 disparities, though the number of studies 
providing data on DQB1 is far more limited. In regard to the 
importance of HLA-DQB1 matching, certain studies have 
shown that DQB1 incompatibilities appear to gain significance 
when combined with DRB1 or other HLA mismatches.12;13 This 
also seems to apply for mismatches located in HLA-DRB3/4/5 
loci, although it should be noted that the number of studies 
addressing this is rather small.11,29,30 When it comes to the effect 
of single HLA-DRB1 discrepancies, study results tend to be 
more uncertain. In a large NMDP/CIBMTR study22 as well as 
in some other studies,17,21,24,31 single mismatches in HLA-DRB1 
were associated with significantly lower overall survival (OS) 
and higher transplant-related mortality (TRM). In contrast, 
two Japan Marrow Donor Program (JMDP) studies, the first 
published in 199832 and the second in 2015,13 in concordance 
with the results from Pidala et al.26 reported no statistically 
significant association between DRB1 mismatches and sur-
vival. Nonetheless, DRB1 disparities were found to confer a 
significantly higher risk for grade II-IV acute GvHD (aGvHD) 
(Risk Ratio (RR):1.24, P<0.001). Interestingly, two large 
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the impact of each respective locus appears more variable, 
as it can be modified by a series of other parameters such as 
coexistence of other mismatch (MM), racial particularities, 
donor selection practices and (MM)-permissiveness.1,13,22,25,32,35 
Data on HLA-C and HLA-DPB1 mismatches are reviewed in 
more detail in a separate paragraph.
L e v e L  O f  H L A - m I S m A T C H
The study of Flonemberg et al21 first suggested a differ-
ential impact of antigen- versus allele-level mismatches on 
HSCT outcome. Apart from one study by Horan et al,36 which 
however included exclusively nonmalignant disease patients, 
all subsequent studies addressing this issue14,22,24,26 showed 
that, with the exception of HLA-C,14 allele-level discrepancies 
should be viewed as equally detrimental as antigen-level ones. 
This discordance could stem from the significantly skewed 
distribution of cases with allele- versus antigen-mismatches in 
the HLA-C and -DRB1 loci analyzed in the Flonemberg et al 
study.21 In particular, most of HLA-C mismatches, whose no-
table deleterious effect was in fact one of the main conclusions 
of the study, concerned discrepancies at antigen level (86% 
vs 14%). In contrast, HLA-DRB1 mismatches, were predomi-
nantly mismatches at allele level (85% vs 15%). It is therefore 
possible, that the skewed distribution of mismatches in these 
two loci as to their resolution level, might have confounded the 
meta-analysis studies including 13 studies (n=13,446 trans-
plants)33 and 36 studies (n=100,072 transplants)34 respectively, 
have similarly reported divergent conclusions as to the effect 
of DRB1 single mismatches on overall mortality, despite the 
partial overlapping of data meta-analyzed (Results of the two 
meta-analysis studies are summarized in Table 2). According to 
the bigger in volume meta-analysis of Tie et al,34 DRB1 single 
mismatches were clearly associated with higher (TRM) and 
thus lower survival rates. This was not observed in the smaller 
meta-analysis study from Kekre et al. Last, the findings from 
Kanda et al.25 comparing the impact of single HLA-mismatches 
in two distinct transplantation eras (i.e. 1993-1999 and 2000-
2009) revealed an intriguing correlation between DRB1 single 
mismatch effect and transplantation era. According to their 
results, DRB1 single mismatches in the late period had a 
much more pronounced impact on outcome compared to the 
early one. This may well be attributed to the fact, that DRB1 
mismatches were far more often avoided in the early era on 
account of evidence that clearly demonstrated the deleteri-
ous effects of that mismatch. The small number of DRB1 
mismatched HSCTs of that era probably precluded statistical 
significance as to DRB1 mismatch effect. Progress in GvHD 
protection treatments has allowed for more DRB1 mismatched 
HSCTs in the late era and hence higher statistical power. Gen-
erally, as far as HLA-class II incompatibilities are concerned, 
Table 2. Overview of two big meta-analysis studies 
Risk of overall mortality conferred by individual Hla locus mismatches
Tie et al. Meta-analysis (N=100,072, Nt=36)
Allele Studies* HR (95% CI) P I2
HLA-A 12 1.33 (1.27-1.40) <0.001 0.0%
HLA-B 12 1.35 (1.21-1.50) <0.001 46.7%
HLA-C 14 1.23 (1.17-1.29) <0.001 0.4%
HLA-DRB1 9 1.19 (1.07-1.32) 0.001 42.0%
HLA-DQB1 7 1.07 (0.98-1.17) 0.142 28.8%
HLA-DPB1 8 1.03 (0.97-1.09) 0.460 32.3%
Kekre et al. Meta-analysis (N=13,446, Nt=13)
Allele Studies* HR (95% CI) P I2
HLA-A 4 1.48 (1.19-1.86) 0.001 21.0%
HLA-B 5 1.45 (1.20-1.75) <0.001 0.0%
HLA-C 6 1.58 (1.23-2.01) <0.001 63.0%
HLA-DRB1 3 1.16 (0.84-1.59) 0.363 15.0%
HLA-DQB1 4 0.95 (0.74-1.21) 0.668 4.0%
HLA-DPB1 3 0.99 (0.89-1.10) 0.816 0.0%
Statistical significance is marked in bold. Nt refers to the number of meta-analyzed studies.
*number of studies
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conclusive estimations of the study over the differential effect 
of allele versus antigen HLA mismatches on HSCT outcome. 
Currently, there is general consensus on the irrelevance of 
mismatch level for HLA-A,-B, and-DRB1 incompatibilities. 
In the case of HLA-C, which shall be discussed later, find-
ings suggest that allele- contrary to antigen-level-mismatches 
have minimal impact on HSCT outcome and thus should be 
considered as ‘permissive’ mismatches.37
D I R e C T I O N A L I T y  O f  H L A - m I S m A T C H
Although intuitively one would expect GvH-unidirectional 
or bidirectional mismatches (i.e. Graft vs Host and Host vs 
Graft) to be associated with higher TRM and GvHD rates 
compared to host versus graft (HvG)-unidirectional mis-
matches, data thus far have been rather inconclusive. Sup-
portive evidence for this notion can be found in a study from 
Hurley et al,38 which evaluated the impact of MM directionality 
in 2687 NMDP transplants on HSCT outcome. According to 
their analyses, 7/8 HvG MM were not associated with worse 
outcome in any post-transplant endpoint when compared to 
8/8 M cases. In contrast, GvH-unidirectional and bidirectional 
MM conferred significantly higher risk of TRM and overall 
mortality when compared to 8/8 M transplants. If results were 
underpowered due to the small size of the unidirectional 
groups is yet unknown. A more recent study from Kanda 
et al,39 investigating the impact of HLA MM directionality 
on HSCT outcome in 3756 JMDP transplants, detected no 
particular correlation between directionality and mortality in 
unidirectional MM cases. In this study just like in the study of 
Hurley et al,38 the distribution of MM cases on account of their 
directionality was similarly skewed, with only 83 transplants 
in each unidirectional group versus 1020 in the bidirectional 
one. The markedly low number of unidirectional MM cases 
overall makes it evidently hard for even large cohort studies to 
identify statistically significant effects. Furthermore, the low 
likelihood (about 14%) of encountering a 7/8 unidirectionally 
MM donor upon donor- selection, makes the consideration of 
MM directionality rather irrelevant for now.
N U m B e R  O f  H L A - m I S m A T C H e S
It has long been established that multiple mismatches 
confer exponentially higher risk of mortality and GvHD and 
therefore should be avoided at least in a bone marrow (BM) 
or peripheral blood stem cell (PBSC) setting.32,40-43 As mostly 
adverse is considered the combination of HLA-class I and II 
MM with respect to acute GvHD risk, while accumulation of 
HLA-class I MM has been shown to correlate with increased 
risk of graft failure.32,40-42 Moreover, according to the observa-
tions of Petersdorf et al,12 multiple mismatches containing one 
DQB1 MM have been found to confer significantly higher risk 
of mortality as compared to other multiple MM not including 
DQB1. The latter was also partially supported by the findings 
of Morishima et al,13 who detected an aggravating effect of 
HLA-DQB1 MM on overall MM impact when combined with 
HLA-DRB1 MM. The detrimental effect of ≥ 2MM was also 
clearly demonstrated in the two large meta-analysis studies 
mentioned before.33,34  
T H e  S p e C I A L  C A S e S  O f  H L A - C  A N D  H L A - D p B 1 
m I S m A T C H e S
HLA-C and HLA-DPB1 constitute special cases, as they 
are perhaps the only HLA loci for which ‘permissive’ MM have 
been clearly identified.37,44 Moreover, they are both lower ex-
pressed on cell surface compared to their respective HLA-class 
counterparts.45,46 Another interesting analogy is the existence 
of two immunogenicity models, which aim at explaining the 
‘permissiveness’ of specific MM constellations for both loci. 
For HLA-DPB1 the two models are:
 a) The long established T-cell epitope (TCE) model first 
described by Zino et al,44 which attributes the distinct im-
munogenicity profile of respective HLA-DPB1 alleles to the 
existence or not of specific shared T-cell epitopes known to 
stimulate alloreactive T-cells. In other words alleles carrying 
these epitopes are considered highly immunogenic, while 
those that don’t, low immunogenic. Alleles carrying the shared 
epitopes, yet inducing a milder alloreactive T-cell response, 
constitute a separate intermediate group. At the moment, 
there are two established versions of this TCE model, which 
only minimally differ from one another. A further refinement 
of the TCE-model has been recently proposed by the novel 
concept of ΔFD47 (i.e. the net difference between functional 
distance (FD)-scores of mismatched HLA-DPB1 alleles in 
patient and donor). Before practical implementation of this 
latest algorithm however, further research is warranted.  
b) A so-called expression-model, was recently described 
by Petersdorf et al,48 which considers expression-related 
polymorphisms in order to explain the differential immuno-
genicity of HLA-DPB1 alleles. Specifically, alleles in linkage 
with the rs9277534A were found by means of a quantitative 
polymerase-chain-reaction assay to be lower expressed com-
pared to the rs9277534G alleles.48 Petersdorf et al in the same 
study48 including 1441 11/12 MUD transplants, observed that 
rs9277534G-linked HLA-DPB1 MM conferred higher risk of 
aGvHD compared to rs9277534A-linked ones, which were 
subsequently defined as ‘permissive’. The two models are to a 
high extent overlapping, yet some significant discrepancies will 
need to be clarified (e.g. HLA-DPB1*17:01) by future studies. 
In the case of HLA-C, similarly an epitope-like- and 
an expression-model have been described.49,50 According to 
the first epitope-like model, accumulation of discrepancies 
between mismatched alleles in seven key amino acid (aa)
residues in the ARS (i.e. 9, 97, 99, 116, 152, 156 and 163) may 
be proportionally associated with worse outcomes, although 
further research is required before definite conclusions can 
be drawn.51,52 It is of interest, that the results from in vitro 
cytotoxic T-lymphocyte precursor frequency (CTLp-f) assay 
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analyses evaluating the immunogenicity profile of various 
HLA-C MM combinations were concordant with the afore-
mentioned model, as MM with 0-1 differences in the seven key 
aa had a negative or weak CTLp-f assay (e.g. C*03:03-03:04 
and C*07:01-07:02), while C MM with 5-6 key aa disparities 
(C*15:02-14:02 in B*51 positive patients and C*04:01-12:03 
in B*35 positive patients) had a positive one.53 Nevertheless, 
another similar model proposed by Joris et al54 aiming at pre-
dicting cytotoxic T-cell alloreactivity on account of the number 
of aa discrepancies in the α-helices and β-sheet between the 
mismatched C alleles, failed to establish such a correlation in 
a clinical dataset of 171 9/10 and 168 10/10 MUD transplants.55 
A second expression-model was proposed a few years ago 
again by Petersdorf et al.50 In this study a proxy model, which 
was based on the findings of a previous study associating 
high HLA-C expression levels with lower HIV viral load,56 
was implemented for the estimation of HLA-C expression 
variation in distinct C MM combinations and its impact on 
HSCT outcome. According to their findings, MM expression 
levels were directly correlated with worse outcomes in a pro-
portional fashion. Interestingly, MM constellations that were 
previously identified as permissive by cellular assays, were 
strongly linked to lower expression levels (e.g. C*03:03-03:04 
and C*07:01-07:02). 
Finally, one more intriguing coincidence is that HLA-C and 
HLA-DPB1 MM are the only HLA MM associated with sig-
nificantly lower relapse rates.34 For HLA-DPB1 in particular, 
according to the findings of Fleischhauer et al,57 a permissive 
MM donor could be from an immunological standpoint prefer-
able to a fully matched one in a high-risk malignant setting, as 
permissive MM were found to confer significantly lower risk of 
relapse without substantially increasing the risk of aGvHD. If 
this could also hold true in a HLA-C permissive MM context 
is yet to be determined. According to current data however 
and at least as far as HLA-C non-permissive incompatibilities 
are concerned, any potential benefit from lower relapse is 
expected to be outweighed by significantly higher TRM rates.
N O N - H L A  f A C T O R S  T H A T  I N f L U e N C e 
T H e  I m p A C T  O f  H L A  D I S p A R I T y  
O N  H S C T  O U T C O m e
The objective of this section is to offer the reader an over-
view of non-HLA parameters that could potentially influence 
the overall effect of HLA disparities on HSCT outcome. 
D I S e A S e  A S S O C I A T e D  pA R A m e T e R S :  
e N T I T y  A N D  S T A g e
Allogeneic HSCT has long been established as standard 
of care for a plethora of primarily hematological malignant 
as well as nonmalignant disease entities.58,59 According to 
statistical data from American as well as European research 
groups,60,61 acute leukemia is the most common indication 
for HSCT comprising more than 50% of total allogeneic 
transplant cases worldwide. This development is mainly due 
to the curative potential of allogeneic HSCT thanks to the 
graft vs leukemia (GvL) component of alloreactivity.62 It is 
clear, that in a nonmalignant disease setting this beneficial 
aspect of HSCT deriving from partial incompatibility between 
patient and donor is not applicable. Could this subsequently 
mean that HLA disparities in a nonmalignant disorder setting 
could be more detrimental as to survival rates compared to 
a malignant one? This question was addressed by Horan et 
al36 in a study of 663 BM and PBSC transplants that were per-
formed exclusively in patients with nonmalignant disorders. 
As expected, single as well as double MM irrespectively of 
resolution level were associated with higher mortality risks. 
Interestingly, in this nonmalignant disease dataset higher 
mortality as a result of HLA incompatibility was associated 
with significantly higher graft failure and not higher acute 
GvHD or TRM as one would intuitively expect, considering 
previous results in malignant disease cohorts.22,23 This could 
be attributed to two main factors.63 Although the prevalence 
of donor specific antibodies (DSA) was not investigated in 
the aforementioned study, considering the high transfusion 
burden of patients requiring HSCT due to a non-malignant 
hematological disorder (i.e. aplastic anemia, thalassemia, 
osteopetrosis etc.), it is plausible to assume that at least a 
significant part of antigen-MM related graft failures could 
have been the result of humoral alloreactivity (i.e. antibody 
mediated rejection). Furthermore, nonmalignant disease 
patients’ immune system is expected to be more apt to hinder 
engraftment, considering that it has not been compromised by 
additional chemotherapy prior to pre-transplant condition-
ing.  However, the absence of association between HLA MM 
and acute GvHD, non-relapse mortality (NRM) or TRM in 
the malignant disease cohort most likely stemmed from the 
extensive use of graft manipulation (i.e. receipt of lymphocyte 
depleting antibody or ex-vivo T-cell depleted graft) reported.19 
Another disease relevant parameter that has been shown 
to correlate with the HLA MM effect is disease stage. Ac-
cording to the findings of Petersdorf et al,12 the detrimental 
impact of HLA disparities was far more prominent in low-risk 
disease patients. This could be intuitively attributed to the fact 
that in a low-risk disease setting any potential benefit from 
GvL is far weaker and thus more evidently outbalanced by 
HLA-MM derived GvHD. It should be noted however, that in 
that cohort, low-risk were exclusively CML patients in chronic 
phase. After the broad and successful implementation of ty-
rosine kinase inhibitors (TKIs) for the treatment of CML,64 
allogeneic HSCT has ceased being considered standard of care 
for this condition, therefore new cohorts that would better 
reflect current practice are mandatory in order to estimate 
the applicability of the Seattle group results in non-CML low 
risk disease patients.
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R e C I p I e N T  A g e
Although it is generally accepted that younger patient age 
is associated with better HSCT outcome, the direct correlation 
between HLA MM impact on HSCT and recipient age has 
only recently been addressed by Fürst et al. in a retrospective 
multicenter cohort of 3019 uHSC transplants.15 Interaction 
analysis of the two parameters revealed an unambiguous asso-
ciation between higher HLA-MM-conferred mortality-risk and 
advanced disease age, especially in double mismatched (8/10) 
cases. More specifically, patients aged over 55years trans-
planted with 8/10 matched donors showed a disproportion-
ally higher risk of mortality when compared to 8/10 matched 
transplanted patients of younger age groups (HR: 1.14, 1.40 
and 2.27 in patients aged 18-35, 36-55 and >55 respectively). 
When the HR of 8/10 elderly patient group transplants was 
estimated in reference to 10/10 matched patients aged 18-35 
it exponentially increased to 3.48. Before definite conclusions 
can be drawn, these findings will have to be confirmed by 
other independent cohorts. Given nevertheless, the significant 
proportion of elderly patients in this cohort (n=1195/3019) as 
well as the high representation of latest era transplantations 
(n=1671/3019 for 2008-2011 and n=2610/3019 for 2004-2011), 
it seems rather reasonable to follow the author’s recommenda-
tion for best possible HLA matching in patients over 55 years 
of age along with consideration of alternative HSCT options 
in case a ≥9/10 matched donor is unavailable. 
g R A f T  m A N I p U L A T I O N
Various T-cell depletion (TCD) techniques have been 
developed over the years.65 Despite the promising results of 
these methods with regard to GvHD and TRM dampening, 
the absence of proven beneficial impact on overall survival 
due to delayed immune reconstitution, higher incidence of 
graft failure as well as increased infection prevalence has 
contained the extensive use of TCD in allogeneic HSCT.65 The 
association between HLA MM impact on HSCT outcome and 
graft manipulation, has been repeatedly insinuated in many 
studies underscoring the significantly lower relative risk of 
grade II-IV aGvHD in TCD transplants19;65. Given the estab-
lished association between HLA MM and aGvHD incidence, 
it becomes apparent that in a mismatched HLA unrelated 
HSCT (uHSCT) setting, TCD can significantly mitigate the 
proportionally higher risk of TRM conferred by HLA MM.19 
This was also shown in the nonmalignant cohort study of 
Horan et al36 previously mentioned. New focused strategies 
in the field of graft manipulation, which aim at improving the 
immune reconstitution as well as the GvL potential of TCD 
grafts, may prove to be an efficient antidote to the deleterious 
effect of HLA disparities on HSCT outcome in the near future. 
(Chimeric Antigen Receptor (CAR) T-cell therapy, Bi-specific 
T-cell engagers, checkpoint inhibitors to control relapse follow-
ing allo- HSCT along with adoptive use of regulatory T-cells 
(Tregs) and suicide gene manipulation to improve the risk of 
post-transplant GVHD post-transplant are some examples of 
these developing treatments).65 
C O N D I T I O N I N g  R e g I m e N
The constantly growing use of reduced intensity condi-
tioning (RIC) regimens in the modern transplantation era 
has significantly altered the patient age range and thus the 
composition of the late years’ cohorts.66 Given that most of 
the data regarding the effect of HLA MM on post-transplant 
outcome mostly derive from transplantations performed in 
earlier time periods, when RIC transplants accounted for only 
a small fraction of cases, it was foreseeable that the impact of 
HLA matching in a RIC uHSCT setting would sooner or later 
be addressed by researchers. Two independent groups, one 
in the US16 and one in Japan17 explored the consequences of 
HLA disparities in a non-myeloablative conditioning (MAC) 
environment. Both studies detected higher mortality risks 
associated with HLA MM, with the respective relative risk 
values lying within the range of those previously reported in 
MAC cohorts.21,22,25 Despite the relatively high number of cases 
included in both studies (n=2588 for Verneris et al., n=1130 
for Yokoyama et al.) subgroup analyses aiming at discerning 
the differential effect of HLA incompatibilities with reference 
to locus or resolution level of MM had limited power due to 
the broad scattering of cases. Under this prism, the finding of 
Verneris et al16 regarding the non-identified ‘permissiveness’ 
of HLA-C*03:03/03:04 MM or TCE permissive DPB1 MM 
should be viewed with caution. In line with this, the absence 
of notable difference in mortality risk conferred by single 
and double mismatches with reference to full 8/8 match (i.e. 
hazard ratio [HR], 1.34; P = .0024 for 7/8 match; HR, 1.33; 
P = .035 for 6/8 match) found in the Japanese cohort17 could 
also be attributed to cohort-size limitations in the respective 
subgroups. However, the direct association between MM num-
ber and risk of NRM and GvHD observed16, adds validity to 
the assumption that an enhanced HLA-MM-associated GvL 
effect may be more pronounced in a RIC compared to a MAC 
HSCT setting. If this assumption, along with the finding that 
HLA MM impact appeared to be less significant in the later 
transplantation years, hold, remains to be resolved by future 
RIC-specific studies. 
C m v  S e R O - S T A T U S  m A T C H I N g
The significance of CMV sero-status matching between 
recipient and donor is acknowledged and hence considered 
routinely upon donor selection.7 The potential interaction 
however, between this parameter and HLA matching had 
not but only recently been reported in literature. Particularly, 
Shaw et al18 in their study of 1271 malignant disease patients 
receiving T-cell depleted allografts reported a clear connec-
tion between CMV and HLA matching, with combined MM 
being identified as the most deleterious combination. Perhaps 
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the most interesting finding of this study was the potential 
of CMV-matching to partly abrogate the detrimental effect 
of HLA MM on outcome. Although these data are certainly 
intriguing with practical implications as to the prioritization 
of donor selection criteria, it should be underscored that these 
results concerned exclusively TCD transplants. If this also ap-
plies to non-manipulated grafts is something that will have to 
be explored by future studies.
T y p e  O f  T R A N S p L A N T A T I O N :  p B S C ,  
B O N e  m A R R O w,  U m B I L I C A L  C O R D  B L O O D  
O R  H A p L O I D e N T I C A L
Graft source varied among the respective studies listed 
in Table 1. Despite the differences observed as to the indi-
vidual effect of distinct HLA disparities on survival, there 
were no marked discordances on HLA MM-related mortal-
ity risk between BM and PBSC allogeneic transplants. For 
umbilical cord blood (UCB), it appears that single HLA 
MM regardless of locus had no significant impact on overall 
mortality. However, according to the findings of Eapen et al 
in two retrospective studies,27,67 HLA-matching had a notable 
impact on TRM/NRM with HLA mismatching exhibiting a 
cumulative effect. This was also confirmed in a later study 
by Brunstein et al68 concerning double unit UCB transplants. 
Moreover, it is of note, that certain UCB studies69 have im-
plied an interactive connection between total nuclear count 
(TNC) per unit and HLA-matching, suggesting combined 
consideration of these two parameters for superior outcomes. 
As far as haploidentical transplantations are concerned, the 
role of better HLA matching in outcome remains unclear, 
as there is no supportive evidence thus far indicating better 
post-transplant results linked to better HLA-matched grafts 
in this transplantation setting,70,71 with the exception of HLA-
B matching in non-shared haplotype, which was found to be 
significantly relevant in just one Chinese study.72 Considering, 
nevertheless that only a few and limited in size studies have 
addressed this question, one cannot preclude over-turning of 
this conception in the future.
C O N C L U S I O N
With this review we aimed at offering the reader a compre-
hensive overview of current scientific knowledge on the impact 
of HLA-matching in different HSCT settings, evaluating 
separately HLA- and non-HLA-parameters that may modify 
it. From presented data, it becomes apparent that any kind of 
HLA disparity should be viewed within the context of HSCT 
as a whole and not independently from other transplantation-
related factors, seeing that many of the latter can substantially 
alter HLA MM effect on post-transplant outcomes.
R e C O m m e N D A T I O N  T I p S  f O R  B e T T e R 
A S S e S S m e N T  O f  H L A  D I S pA R I T I e S  
I N  D I S pA R A T e  H S C T  S e T T I N g S
 - Single HLA MM irrespective of locus, with the exception 
of HLA-DQB1 and DPB1, are associated with higher risk 
of mortality and should therefore be avoided 
 - Antigen vs allele mismatch is only relevant in HLA-C dis-
parities, with HLA-C MM at allele level being considered 
as ‘permissive’
 - Single DQB1 MM appear to be well tolerated, yet should 
be avoided when combined with incompatibilities in other 
loci
 - Accumulation of HLA MM is always detrimental, hence 
should be avoided even in a UCB setting (i.e. <7/8 match 
in PBSC and BM and <4/6 match in UCB)
 - Permissive HLA-DPB1 MM might confer superior out-
comes in a malignant disorder setting compared to M and 
non-permissive MM
 - Up to now there is no substantial evidence supporting 
any consideration of HLA-MM directionality in regard 
to donor selection
 - Double HLA MM have been shown to be more deleterious 
in elderly patients and should thus be avoided
 - CMV sero-status matching should be considered upon 
donor selection, especially in a mismatched TCD setting
 - Best possible matching should be prioritized in low-risk- as 
well as in nonmalignant disease patients
p R O S p e C T S  A N D  f U T U R e  C H A L L e N g e S
The holy grail of HSCT had always been diminishing the 
detrimental transplantation-related alloreactivity (i.e. GvHD) 
without undermining its positive GvL side. With the exception 
of permissive HLA-DPB1 MM, current data affirm that any 
putative positive effect of HLA MM on relapse is outweighed 
by a proportionally higher increase in TRM risk.57 New ad-
vances in the direction of identifying ‘permissive’ disparities 
similar to HLA-DPB1 in other loci through identification of 
shared immunogenic epitopes, is an undoubtedly promising 
strategy. In parallel, progress in the field of biomolecular 
engineering and particularly in the development of more so-
phisticated GvHD prophylaxis regimens as well as techniques 
enhancing GvL and engraftment, is expected to completely 
revolutionize HSCT as we know it today. A new HSCT era 
has already started. “Le roi est mort, vive le roi”.
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